Harrow Health, Inc. (HROW) Insider Trading Activity

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.

Show less

Over the last 12 months, insiders at Harrow Health, Inc. have bought $468,720 and sold $9.65M worth of Harrow Health, Inc. stock.

On average, over the past 5 years, insiders at Harrow Health, Inc. have bought $2.17M and sold $4.15M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BAUM MARK L (CHIEF EXECUTIVE OFFICER) — $302,000. BOLL ANDREW R. (PRESIDENT AND CFO) — $104,650. Graves Adrienne L (director) — $31,070.

The last purchase of 1,000 shares for transaction amount of $31,000 was made by SILVERNAIL LAUREN P (director) on 2026‑05‑18.